QUOTE AND NEWS
Benzinga  Sep 23  Comment 
TG Therapeutics, Inc. (Nasdaq: TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"). The Company and...
SeekingAlpha  Sep 19  Comment 
By Mrs. BullBear: On Monday, September 15, 2014 TG Therapeutics Inc. (NASDAQ:TGTX) announced that they had reached an agreement with the FDA on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101, its...
Benzinga  Sep 15  Comment 
TG Therapeutics, Inc. (Nasdaq: TGTX) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis approach of a...
SeekingAlpha  Sep 4  Comment 
By Tal Davidson: Throughout my investing life, I have discovered that companies experiencing short term problems, yet favorable long term trends, and their management is honest and committed, urn out to be lucrative investment opportunities. These...
SeekingAlpha  Aug 21  Comment 
By Marshall Hargrave: Tredegar (NYSE:TG) posted Q2 earnings of $0.11, or $0.34 per share (excluding special items). The company lacks analyst coverage, and had no consensus estimate for the quarter. Revenues were down 7.7% y/y. Its operating...
SeekingAlpha  Aug 8  Comment 
Tredegar (NYSE:TG) Q2 2014 Earnings Call August 08, 2014 8:30 am ET Executives Neill Bellamy - Nancy M. Taylor - Chief Executive Officer, President and Director Kevin A. O'Leary - Chief Financial Officer, Vice President and...
SeekingAlpha  Jul 22  Comment 
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2014 Earnings Conference Call July 22, 2014 08:30 AM ET Executives Jenna Bosco - Director, IR Sean Power - CFO Mike Weiss - Interim CEO Analysts Joe Pantginis - ROTH Capital Partners ...
Motley Fool  Jul 22  Comment 
TG Therapeutics delivers impressive preliminary phase 1 clinical data for its investigational combo designed to treat blood cancers. Find out why investors are giving this data release a mixed review.
StreetInsider.com  Jul 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TG+Therapeutics+%28TGTX%29+Adopts+Stockholder+Rights+Plan/9676677.html for the full story.
Benzinga  Jul 2  Comment 
In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00. In the report, MLV & Co noted, “We now raise our PT on TGTX...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki